Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts

By H. Skiadopoulos M.   Tao T.   Surman S.R.   Collins P.L.   Murphy B.R.  

Vaccine, Vol. 18, Iss. 5, 1999-10 ,pp. : 503-510

Elsevier

Access to resources Recommend Favorite

Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one

By Hurwitz J.L.   Soike K.F.   Sangster M.Y.   Portner A.   Sealy R.E.   Dawson D.H.   Coleclough C.  

Vaccine, Vol. 15, Iss. 5, 1997-04 ,pp. : 533-540

Elsevier

Access to resources Recommend Favorite

Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates

By Jin H.   Cheng X.   Traina-Dorge V.L.   Park H.J.   Zhou H.   Soike K.   Kemble G.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3647-3652

Elsevier

Access to resources Recommend Favorite

A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to P

By Tao T.   Davoodi F.   Cho C.J.   Skiadopoulos M.H.   Durbin A.P.   Collins P.L.   Murphy B.R.  

Vaccine, Vol. 18, Iss. 14, 2000-02 ,pp. : 1359-1366

Elsevier

Access to resources Recommend Favorite

African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection

By Durbin A.P.   Elkins W.R.   Murphy B.R.  

Vaccine, Vol. 18, Iss. 22, 2000-05 ,pp. : 2462-2469

Elsevier

Access to resources Recommend Favorite